Ann Oxford University Spinout has raised £ 7.3m to develop a device that can prevent cerebral hemorrhage.
Oxford Intravascular Is developing a cure for cerebral aneurysms, saying it will overcome the challenges of existing medical devices.
Cerebral aneurysms are surprisingly common and affect 1 in 50 people. If the patent ruptures, they are likely to die or suffer permanent brain injury.
The company has developed a microstent called OxiFlow️ (bottom), using “origami” engineering that can be inserted into the cerebral blood vessels via minimally invasive inguinal access.
It is located throughout the base of the aneurysm and causes the aneurysm to contract and heal.
Developed by world-leading professors in neuroradiology and engineering, this next-generation “flow diverter” can be placed more accurately and safely than existing therapies, reducing the risk of complications and multiple You need to use the device.
“The current device market for cerebral aneurysms is well worth over $ 1 billion and is growing rapidly year-over-year,” said CEO Mike Karim.
“One of the biggest challenges in treating neurovascular disease is to have a highly effective device with minimal adverse events.
“Research shows that treatment devices have the challenge of landing accurately and maintaining their position open, so multiple attempts are often made to place the treatment device. This can lead to adverse events and multiple attempts. Devices may be used.
“Procedures typically cost more than $ 50,000 to treat cerebral aneurysms, and next-generation flow divertors that overcome unmet needs simply provide more effective, safer and more cost-effective treatment opportunities. It benefits more patients.
“We plan to use this money to bring Oxford. In the blood vessel Take breakthrough technology to the next level and get clinical data from human research. “
Financing includes a £ 3m investment from new investor Vulpes Investment Management, who participated to lead the round Additio Investment group.
Existing Investor Oxford Sciences Innovation PLC, Park walk Advisor, Perivoli Innovation, Oxford Investment Consultants, Oxford University, and individuals followed.
Martin Diggle, Life Sciences Portfolio Manager at Vulpes Investment Management, commented: “The Vulpes life sciences team is excited to take part in the next phase of the development of innovative technology for Oxford End Vascular.
“We believe this platform has the potential to become a world leader in that area.”
Alun Williams, Investment Director Park walk An advisor, a major investor in UK university spinouts, said:Park walk We are pleased to have invested in the internal blood vessels of Oxford.
“This salary increase is a testament to the extraordinary work and innovation of a great team of development engineers and inventors, helping the company through the next phase of research.”
A device designed with origami “can prevent cerebral hemorrhage”
Source link A device designed with origami “can prevent cerebral hemorrhage”